Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Chemo Regimens for High-Grade Gliomas

Cochrane; 2017 Jul 26; Parasramka, Talari, et al

Publish date:: August 1, 2017

Chemotherapy-naive patients with high-grade glioma at first recurrence had similar survival and time-to-progression outcomes, according to a Cochrane review of a randomized trial involving nearly 450 individuals. The study compared procarbazine/lomustine/vincristine and temozolomide (TMZ) chemotherapies. In addition to comparable survival outcomes, adverse events were also similar (based on moderate quality evidence). Quality of life scores statistically favored TMZ, but the difference was not clinically relevant (based on low quality evidence).

The investigators advised interpreting the results cautiously since they are based on analysis of a single trial.

Citation:

Parasramka S, Talari G, Rosenfeld M, Guo J, Villano J. Procarbazine, lomustine and vincristine for recurrent high-grade glioma. Cochrane Database of Systematic Reviews. 2017, Issue 7. Art. No.: CD011773. doi:10.1002/14651858.CD011773.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in CNS/Brain Cancer

Dexamethasone may ‘jeopardize’ benefit of immunotherapy in glioblastoma,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Immunotherapy could fill unmet need in leptomeningeal metastases,

Molecular features of medulloblastoma may help personalize radiotherapy,

‘Tour de force’ study reveals therapeutic targets in 38% of cancer patients,